What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?

Journal of Cardiovascular Medicine

Volumn 11, Issue 11, 2010, Pages 858-860

  Ahmed, Mohamed H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cardiovascular disease; hyperlipidaemia; niacin

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROSTAGLANDIN D2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; INSULIN SENSITIVITY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); NIACIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77958172043     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833dadc3     Document Type: Short Survey

References (26)

1. Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand 1968; 183:457-465.
2. Menon RM, Adams MH, Gonzalez MA, Tolbert DS, Leu JH, Cefali EA. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45:448-454. (Pubitemid 47243941)
3. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007; 19:151-157. (Pubitemid 46208773)
4. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992; 93:102-104.
5. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. JAMA 1990; 264:723-726. (Pubitemid 20246864)
6. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158:429-441.
7. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
8. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
9. Zhao SP, Yang J, Li J, Dong SZ, Wu ZH. Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Int J Cardiol 2008; 124:172-178. (Pubitemid 351173356)
10. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101:625-630.
11. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009; 5:901-908.
12. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
13. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
14. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart DiseaseSecondary Prevention Study bycombined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.
15. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592. (Pubitemid 33126837)
16. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517. (Pubitemid 39612564)
18. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787-1794.
19. Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 2010; 15:158-166.
20. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121:110-122.
21. Ahmed MH. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream? Diabetes Technol Ther 2008; 10:328-329.
22. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32:1924-1929.
23. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3671-3689.
24. Liu J, Grundy SM, Wang W, Smith SC Jr, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007; 153:552-558. (Pubitemid 46440680)
25. Zhao D, Grundy SM, Wang W, Liu J, Zeng Z, Wang W, et al. Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged chinese. Am J Cardiol 2007; 100:835-839. (Pubitemid 47268276)
26. Libby A, Meier J, Lopez J, Swislocki AL, Siegel D. The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. Metab Syndr Relat Disord 2010; 8:79-84.